CASI Pharmaceuticals (CASI) Given “Buy” Rating at HC Wainwright

CASI Pharmaceuticals (NASDAQ:CASI)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Monday. They presently have a $4.50 price target on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 16.28% from the stock’s current price.

The analysts wrote, “Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Acquisition of Sandoz Portfolio Could Lead to Commerical Launch in 12 Months; Reiterate Buy A transformative acquisition. On January 26, CASI announced the acquisition of an abbreviated new drug application (ANDA) portfolio from Sandoz, the generic drug division of Novartis (NVS; not rated), for $18M. The portfolio includes several essential medications such as Entecavir, Lisinopril, Methimazole, and Midodrine and covers a broad spectrum of drugs such as antivirals, anti-depressants, hypertension drugs, and anti-inflammatory drugs. In our view, the acquisition of these 25 approved and 4 pending ANDAs is a transformative event for the company. With the worldwide ANDA data exclusivity, CASI can now quickly become a commercial force in both China and the US.””

Separately, Maxim Group set a $4.00 price objective on shares of CASI Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 14th.

CASI Pharmaceuticals (CASI) opened at $3.87 on Monday. The firm has a market cap of $270.53, a PE ratio of -25.80 and a beta of 1.08. CASI Pharmaceuticals has a 12 month low of $0.91 and a 12 month high of $4.84.

CASI Pharmaceuticals (NASDAQ:CASI) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.03) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. analysts predict that CASI Pharmaceuticals will post -0.13 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/29/casi-pharmaceuticals-casi-given-buy-rating-at-hc-wainwright.html.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply